Multiple Myeloma Research Consortium

The mission of the Multiple Myeloma Research Consortium (MMRC) is to champion collaboration with and integration across academia and industry and to focus on speed and innovation to bring the most promising multiple myeloma treatments to patients faster.

The MMRC comprises 14 member institutions nationwide that form its clinical trials network.

To date, the MMRC has opened through its clinical trials network 22 clinical trials with industry partners – including Novartis, Celgene, Merck, and Proteolix.

MMRC clinical trials are also designed to include correlative studies to better understand what drugs are most effective in treating various sub-groups of patients with myeloma, laying the foundation for the development of personalized medicine.

It was designed to rapidly accelerate progress made against multiple myeloma by significantly improving the understanding of the biology of the disease.